Platelet activation in Alzheimer's disease: From pathophysiology to clinical value

Current Vascular Pharmacology

Volumn 10, Issue 5, 2012, Pages 626-630

  Laske, Christoph ^a   Sopova, Kateryna ^a   Stellos, Konstantinos ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Alzheimer's disease; Platelet activation; Treatment targets; Vascular risk factors

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANTIHYPERTENSIVE AGENT; BETA SECRETASE; CHOLINESTERASE INHIBITOR;

ALZHEIMER DISEASE; ANTIHYPERTENSIVE THERAPY; DISEASE COURSE; HUMAN; PATHOPHYSIOLOGY; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; BLOOD PLATELETS; DEMENTIA; HUMANS; INFLAMMATION; PLATELET ACTIVATION; PLATELET ADHESIVENESS; RISK FACTORS;

EID: 84864538830     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112801784657     Document Type: Review

References (66)

1. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010; 362: 329-44.
2. Kivipelto M, Helkala EL, Laakso MP, et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-51.
3. De la Torre J. Alzheimer̀s disease as a vascular disorder: nosological evidence. Stroke 2002; 33: 1152-62.
4. Qiu C, Winblad B, Fastbom J, Fratiglioni L. Combined effects of APOE genotype, blood pressure, and antihypertensive drug use on incident AD. Neurology 2003; 61: 656-60.
5. Becker-Barroso E. More support for vascular basis of Alzheimer̀s disease. Lancet Neurol 2005; 4: 598-99.
6. Kumar-Singh S, Pirici D, McGowan E, et al. Dense-core plaques in Tg2576 and PSAPP mouse models of Alzheimer̀s disease are centered on vessel walls. Am J Pathol 2005; 167: 527-43.
7. Mielke MM, Rosenberg PB, Tschanz J, et al. Vascular factors predict rate of progression in Alzheimer disease. Neurology 2007; 69: 1850-8.
8. Helzner EP, Luchsinger JA, Scarmeas N, et al. Contribution of vascular risk factors to the progression in Alzheimer disease. Arch Neurol 2009; 66: 343-8.
9. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA 1997; 277: 813-7.
10. Song IU, Kim JS, Kim YI, Eah KY, Lee KS. Clinical significance of silent cerebral infarctions in patients with Alzheimer disease. Cogn Behav Neurol 2007; 20: 93-8.
11. Forette F, Seux ML, Staessen JA, et al. Systolic Hypertension in Europe Investigators. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046-52.
12. Deschaintre Y, Richard F, Leys D, Pasquier F. Treatment of vascular risk factors is associated with slower decline in Alzheimer disease. Neurology 2009; 73: 674-80.
13. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 2672-713.
14. Gawaz M, Stellos K, Langer HF. Platelets modulate atherogenesis and progression of atherosclerotic plaques via interaction with progenitor and dendritic cells. J Thromb Haemost 2008; 6: 235-42.
15. Sevush S, Jy W, Horstman LL, Mao WW, Kolodny L, Ahn YS. Platelet activation in Alzheimer disease. Arch Neurol 1998; 55: 530-6.
16. Colciaghi F, Marcello E, Borroni B, et al. Platelet APP, ADAM 10 and BACE alterations in the early stages of Alzheimer̀s disease. Neurology 2004; 62: 498-501.
17. Prodan CI, Ross ED, Stoner JA, Cowan LD, Vincent AS, Dale GL. Coated-platelet levels and progression from mild cognitive impairment to Alzheimer disease. Neurology 2011; 76: 247-52.
18. Prodan CI, Ross ED, Vincent AS, Dale GL. Rate of progression in Alzheimer̀s disease correlates with coated-platelet levels-a longitudinal study. Transl Res 2008; 152: 99-102.
19. Stellos K, Bigalke B, Panagiota V, et al. Predictive value of platelet activation for the rate of cognitive decline in patients with dementia. J Cereb Blood Flow Metab 2010; 30: 1817-20.
20. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem Biophys Res Commun 1995; 213: 96-103.
21. Li QX, Whyte S, Tanner JE, Evin G, Beyreuther K, Masters CL. Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets. Lab Invest 1998; 78: 461-9.
22. Casoli T, Di Stefano G, Giorgetti B, et al. Release of beta-amyloid from high-density platelets: implications for Alzheimer's disease pathology. Ann N Y Acad Sci 2007; 1096: 170-8.
23. Smith CC. Stimulated release of the beta-amyloid protein of Alzheimer̀ s disease by normal human platelets. Neurosci Lett 1997; 233: 157-9.
24. Olsson A, Vanmechelen E, Vanderstichele H, Davidsson P, Blennow K. Unaltered plasma levels of beta-amyloid(1-40) and betaamyloid(1-42) upon stimulation of human platelets. Dement Geriatr Cogn Disord 2003; 16: 93-7.
25. Sutcliffe JG, Hedlund PB, Thomas EA, Bloom FE, Hilbush BS. Peripheral reduction of β-amyloid is sufficient to reduce brain β-amyloid: implications for Alzheimer's disease. J Neurosci Res 2011; 89: 808-14.
26. Schupf N, Tang MX, Fukuyama H, et al. Peripheral Abeta subspecies as risk biomarkers of Alzheimer's disease. Proc Natl Acad Sci USA 2008; 105: 14052-7.
27. Cammarata S, Borghi R, Giliberto L, et al. Amyloid-beta42 plasma levels are elevated in amnestic mild cognitive impairment. J Alzheimers Dis 2009; 18: 267-71.
28. Laske C, Sopova K, Gkotsis C, et al. Amyloid-β peptides in plasma and cognitive decline after 1 year follow-up in Alzheimer's disease patients. J Alzheimers Dis 2010; 21: 1263-9.
29. Davies TA, Long HJ, Eisenhauer PB, et al. Beta amyloid fragments derived from activated platelets deposit in cerebrovascular endothelium: usage of a novel blood brain barrier endothelial cell model system. Amyloid 2000; 7: 153-65.
30. Herczenik E, Bouma B, Korporaal SJ, et al. Activation of human platelets by misfolded proteins. Arterioscler Thromb Vasc Biol 2007; 27: 1657-65.
31. Neumann K, Farías G, Slachevsky A, Perez P, Maccioni1 RB. Human Platelets Tau: A Potential Peripheral Marker for Alzheimer's Disease. J Alzheimer̀s Dis 2011; 25: 103-9.
32. Forlenza OV, Torres CA, Talib LL, et al. Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. J Psychiatr Res 2011; 45: 220-4.
33. Leroy K, Yilmaz Z, Brion JP. Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Biol 2007; 33: 43-55.
34. Gattaz WF, Forlenza OV, Talib LL, Barbosa NR, Bottino CM. Platelet phospholipase A(2) activity in Alzheimer̀s disease and mild cognitive impairment. J Neural Transm 2004; 111: 591-601.
35. Matsushima H, Shimohama S, Fujimoto S, Takenawa T, Kimura J. Changes in platelet phospholipase C protein level and activity in Alzheimer̀s disease. Neurobiol Aging 1995; 16: 895-900.
36. Bosetti F, Brizzi F, Barogi S, et al. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer̀s disease. Neurobiol Aging 2002; 23: 371-6.
37. Krzystanek E, Krzystanek M, Opala G, Trzeciak HI, Siuda J, Małecki A. Platelet phospholipase A2 activity in patients with Alzheimer's disease, vascular dementia and ischemic stroke. J Neural Transm 2007; 114: 1033-9.
38. Gibson GE, Huang HM. Oxidative processes in the brain and nonneuronal tissues as biomarkers of Alzheimer̀s disease. Front Biosci 2002; 7: 1007-15.
39. Ferrarese C, Begni B, Canevari C, Zoia C, Piolti R, Frigo M, et al. Glutamate uptake is decreased in platelets ftom Alzheimer's disease patients. Ann Neurol 2000; 47: 641-3.
40. Koren P, Diver-Haber A, Adunsky A, Rabinowitz M, Hershkowitz M. Uptake of serotonin into platelets of senile dementia of the Alzheimer type patients. J Gerontol 1993; 48: B93-6.
41. Kumar AM, Sevush S, Kumar M, Ruiz J, Eisdorfer C. Peripheral serotonin in Alzheimer̀s disease. Neuropsychobiology 1995; 32: 9-12.
42. Kessler A, Shinitzky M, Kessler B. Number of platelet dense granules varies with age, schizophrenia and dementia. Dementia 1995; 6: 330-3.
43. Kozubski W, Swiderek M, Kloszewska I, Gwozdzinski K, Watala C. Blood platelet membrane fluidity and the expression of membrane protein receptors in Alzheimer̀s disease. Alzheimer Dis Assoc Disord 2002; 16: 52-4.
44. Prodan CI, Szasz R, Vincent AS, Ross ED, Dale GL. Coatedplatelets retain amyloid precursor protein on their surface. Platelets 2006; 17: 56-60.
45. Prodan CI, Ross ED, Vincent AS, Dale GL. Coated-platelets are higher in amnestic vs. non-amnestic patients with mild cognitive impairment. Alzheimer Dis Assoc Disord 2007; 21: 259-61.
46. Kraemer HC, Tinklenberg J, Yesavage JA. 'How far' vs. 'how fast' in Alzheimer's disease. The question revisited. Arch Neurol 1994; 51: 275-9.
47. Baskin F, Rosenberg RN, Iyer L, Hynan L, Cullum CM. Platelet APP isoform ratios correlate with declining cognition in AD. Neurology 2000; 54: 1907-9.
48. Borroni B, Colciaghi F, Archetti S, et al. Predicting cognitive decline in Alzheimer disease. Role of platelet amyloid precursor protein. Alzheimer Dis Assoc Disord 2004; 18: 32-4.
49. Liu HC, Wang HC, Ko SY, et al. Correlation between platelet amyloid precursor protein isoform ratio and cognition in Alzheimer's disease. J Alzheimers Dis 2007; 11: 77-84.
50. Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis. J Clin Invest 2005; 115: 3378-84.
51. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000; 21: 383-421.
52. Fateh-Moghadam S, Li Z, Ersel S, et al. Platelet degranulation is associated with progression of intima-media thickness of the common carotid artery in patients with diabetes mellitus type 2. Arterioscler Thromb Vasc Biol 2005; 25: 1299-1303.
53. Mathew JP, Rinder HM, Smith BR, Newman MF, Rinder CS. Transcerebral platelet activation after aortic cross-clamp release is linked to neurocognitive decline. Ann Thorac Surg 2006; 81: 1644-49.
54. Ellis EF, Oelz O, Roberts LJ 2nd, et al. Coronary arterial smooth muscle contraction by a substance released from platelets: evidence that it is thromboxane A2. Science 1976; 193: 1135-37.
55. Houston DS, Shepherd JT, Vanhoutte PM. Aggregating human platelets cause direct contraction and endothelium-dependent relaxation of isolated canine coronary arteries. Role of serotonin, thromboxane A2, and adenine nucleotides. J Clin Invest 1986; 78: 539-44.
56. Claassen JA, Diaz-Arrastia R, Martin-Cook K, Levine BD, Zhang R. Altered cerebral hemodynamics in early Alzheimer disease: a pilot study using transcranial doppler. J Alzheimers Dis 2009; 17: 621-9.
57. De la Torre JC. Cerebrovascular and cardiovascular pathology in Alzheimer's disease. Int Rev Neurobiol 2009; 84: 35-48.
58. Borroni B, Akkawi N, Martini G, et al. Microvascular damage and platelet abnormalities in early Alzheimer's disease. J Neurol Sci 2002; 203-204: 189-93.
59. Piletz JE, Sarasua M, Whitehouse P, Chotani M. Intracellular membranes are more fluid in platelets of Alzheimer's disease patients. Neurobiol Aging 1991; 12: 401-6.
60. Kowalska MA, Badellino K. Beta-amyloid protein induces platelet aggregation and supports platelet adhesion. Biochem Biophys Res Commun 1994; 205: 1829-35.
61. Shen MY, Hsiao G, Fong TH, et al. Amyloid beta peptide-activated signal pathways in human platelets. Eur J Pharmacol 2008; 588: 259-66.
62. Islim IF, Beevers DG, Bareford D. The effect of antihypertensive drugs on in vivo platelet activity in essential hypertension. J Hypertens 1992; 10: 379-83.
63. Riondino S, Pignatelli P, Pulcinelli FM, et al. Platelet hyperactivity in hypertensive older patients is controlled by lowering blood pressure. J Am Geriatr Soc 1999; 47: 943-47.
64. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in patients with Alzheimer̀s disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group. Dementia 1996; 7: 293-303.
65. Borroni B, Colciaghi F, Pastorino L, et al. Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment. Arch Neurol 2001; 58: 442-46.
66. Zimmermann M, Borroni B, Cattabeni F, Padovani A, Di Luca M. Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol Dis 2005; 19: 237-42.